Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 6/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984560 | 1.00 | CASP3 (0.59) | CASP3ACEMMEF2F10 | |
| SCHEMBL2707948 | 0.97 | CASP3 (0.55) | CASP3ACEMMEF2F10 | |
| SCHEMBL202944 | 0.97 | CASP3 (0.55) | CASP3ACEMMEF2F10 | |
| SCHEMBL202943 | 0.97 | CASP3 (0.55) | CASP3ACEMMEF2F10 | |
| SCHEMBL17948796 | 0.93 | CASP3 (0.50) | CASP3ACEMMEF2F10 | |
| SCHEMBL12527914 | 0.86 | KMT2A (0.55) | CASP3ACEMMEF2F10 | |
| SCHEMBL12527916 | 0.85 | KMT2A (0.54) | CASP3ACEMMEF2F10 | |
| SCHEMBL12494289 | 0.83 | MMP1 (0.55) | CASP3ACEMMEF2F10 | |
| SCHEMBL12525646 | 0.83 | MMP1 (0.55) | CASP3ACEMMEF2F10 | |
| SCHEMBL7768791 | 0.83 | KMT2A (0.49) | CASP3ACEMMECTSLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275025-A1 | Substituted Lactams and Their Use as Anti-Cancer Agents | NOVARTIS AG | 2008-11-06 | — | — | US | disclosed |
| US-7378410-B2 | Substituted lactams and their use as anti-cancer agents | NOVARTIS AG (CH) | 2008-05-27 | — | — | US | disclosed |
| US-20060281731-A1 | Substituted lactams and their use as anti-cancer agents | BAIR, KENNETH WALTER | 2006-12-14 | — | — | US | disclosed |
| EP-1651633-A1 | SUBSTITUTED LACTAMS AND THEIR USE AS ANTI-CANCER AGENTS | Novartis AG (CH) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005014574-A1 | SUBSTITUTED LACTAMS AND THEIR USE AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-4680392-A | Substituted caprolactam derivatives as antihypertensives | MERCK & CO., INC. (US) | 1987-07-14 | — | — | US | disclosed |
| US-4629787-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1986-12-16 | — | — | US | disclosed |
| EP-0046291-B1 | SUBSTITUTED CAPROLACTAM DERIVATIVES AS ANTIHYPERTENSIVES, PROCESS FOR PREPARING THEM, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND INTERMEDIATES | MERCK & CO. INC. (US) | 1985-12-27 | — | — | EP | disclosed |
| EP-0046291-A2 | Substituted caprolactam derivatives as antihypertensives, process for preparing them, pharmaceutical composition containing them, and intermediates | MERCK & CO. INC. (US) | 1982-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281731-A1 | Substituted lactams and their use as anti-cancer agents | TOP1, TOP2A, TOP2B | CASP3 247/4885ACE 3300/4885MME 3795/4885 |
| US-20080275025-A1 | Substituted Lactams and Their Use as Anti-Cancer Agents | TOP1, TOP2A, MYC | CASP3 107/4885ACE 3345/4885MME 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.